Crossmark

Methodological challenges in Dutch HTA of non-oncological orphan drugs: a retrospective analysis and price comparison using different pricing models

Published Online: 2026-01-08

Authors

Walraven, Jelle https://orcid.org/0009-0007-9859-3754
Kaveh, Mahtab

Uyl - de Groot, Carin
License Information

Text and Data Mining valid from 2026-01-08

Version of Record valid from 2026-02-04
More Information

Article History

Received: 1 May 2025

Accepted: 9 December 2025

First Online: 8 January 2026

Declarations

:

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: MK is an employee of Sanofi, a publicly traded company that markets (orphan) pharmaceuticals. JW is an employee of the Dutch Ministry of Health, in a role that involves managed entry agreements for (orphan) pharmaceuticals. CUdG does not have any competing interests.

Document is current